{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:13:56Z","timestamp":1792178036783,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006564","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2008,4,23]],"date-time":"2008-04-23T00:00:00Z","timestamp":1208908800000}}],"reference-count":59,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006564.pub2","type":"journal-article","created":{"date-parts":[[2008,4,21]],"date-time":"2008-04-21T05:56:47Z","timestamp":1208757407000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Dopamine agonist therapy in early Parkinson's disease"],"prefix":"10.1002","volume":"2010","author":[{"given":"Rebecca","family":"Stowe","sequence":"first","affiliation":[{"name":"University of Birmingham; University of Birmingham Clinical Trials Unit; Division of Medical Sciences, Robert Aitken Institute Edgbaston Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Ives","sequence":"additional","affiliation":[{"name":"University of Birmingham; University of Birmingham Clinical Trials Unit; Division of Medical Sciences, Robert Aitken Institute Edgbaston Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl E","family":"Clarke","sequence":"additional","affiliation":[{"name":"City Hospital, Sandwell and West Birmingham Hospitals NHS Trust; Department of Neurology; Dudley Road Birmingham West Midlands UK B18 7QH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"van Hilten","sequence":"additional","affiliation":[{"name":"Leiden University of Medical Center; Department of Neurology; Albinusdreef 2 Leiden Netherlands 2333 ZA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Hospital de Santa Maria Av. Prof. Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Hawker","sequence":"additional","affiliation":[{"name":"University of Birmingham; University of Birmingham Clinical Trials Unit; Division of Medical Sciences, Robert Aitken Institute Edgbaston Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Shah","sequence":"additional","affiliation":[{"name":"University of Birmingham; University of Birmingham Clinical Trials Unit; Division of Medical Sciences, Robert Aitken Institute Edgbaston Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Wheatley","sequence":"additional","affiliation":[{"name":"Robert Aitken Institute University of Birmingham; Birmingham Clinical Trials Unit - Division of Medical Sciences; Edgbaston Birmingham UK B 15 2 TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gray","sequence":"additional","affiliation":[{"name":"The University of Birmingham; Clinical Trials Unit; Park Grange 1 Somerset Road Edgbaston Birmingham UK B15 2RR"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,4,23]]},"reference":[{"key":"10.1002\/14651858.CD006564.pub2-BIB0001|cit1","first-page":"345","article-title":"Long term bromocriptine treatment in de novo Parkinsonian patients","volume":"48","author":"Herskovits","year":"1988","journal-title":"Medicina (B Aires)"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/1531-8257(200007)15:4<613::AID-MDS1005>3.0.CO;2-F","article-title":"Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two-year follow-up study of previously untreated patients","volume":"15","author":"Kulisevsky","year":"2000","journal-title":"Movement Disorders"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006564.pub2-BIB0003|cit3","first-page":"11","article-title":"A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results","volume":"28","author":"Riopelle","year":"1988","journal-title":"European Neurology"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0004|cit4","article-title":"Bromocriptine and levodopa in early combination in Parkinson's Disease: first results of the Collaborative European Multicentric Trial","volume-title":"Advances in Neurology Vol 53: Parkinson's Disease: Anatomy, Pathology, and Therapy","author":"Olsson","year":"1990"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00002826-199008000-00004","article-title":"CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease","volume":"13","author":"Rascol","year":"1990","journal-title":"Clinical Neuropharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006564.pub2-BIB0006|cit6","first-page":"115 (P611)","article-title":"The safety of pergolide monotherapy in early stage Parkinson's disease: One year interim analysis of a 3-year double-blind randomized study of pergolide versus levodopa","volume":"15","author":"Hundemer","year":"2000","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mds.20724","article-title":"Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study","volume":"21","author":"Oertel","year":"2006","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000008188","article-title":"Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group","volume":"44","author":"Allain","year":"2000","journal-title":"European Neurology"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/mds.10359","article-title":"Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study","volume":"18","author":"Ziegler","year":"2003","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/BF01271230","article-title":"Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study","volume":"103","author":"Przuntek","year":"1996","journal-title":"Journal of Neural Transmission"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000117322","article-title":"Long-term double masked trial of early treatment with L-dopa plus bromocriptine versus L-dopa alone in Parkinson's disease. Interim results","volume":"30","author":"Bakheit","year":"1990","journal-title":"European Neurology"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.53.3.573","article-title":"Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group","volume":"53","author":"Barone","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00023210-200418110-00003","article-title":"The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. The PKDS009 Study Group","volume":"18","author":"Bracco","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1212\/WNL.48.2.363","article-title":"Cabergoline in the treatment of early Parkinson's disease: Results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Study Group","volume":"48","author":"Rinne","year":"1997","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006564.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00003495-199855001-00004","article-title":"Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group","volume":"55","author":"Rinne","year":"1998","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0016|cit16","first-page":"1044","article-title":"Pramipexole vs. levodopa as initial treatment for Parkinson's disease: A 4-year randomized controlled trial","volume":"61","author":"Parkinson Study Group","year":"2004","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","article-title":"Pramipexole vs. levodopa as initial treatment for Parkinson's disease: A randomized controlled trial","volume":"284","author":"Parkinson Study Group","year":"2000","journal-title":"The Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0018|cit18","first-page":"101","article-title":"A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease","volume":"21","author":"Brooks","year":"1998","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group","volume":"342","author":"Rascol","year":"2000","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1034\/j.1600-0404.2000.90295a.x","article-title":"Alpha-dihydroergocryptine in the treatment of de novo Parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study","volume":"101","author":"Bergamasco","year":"2000","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/00002826-199102000-00006","article-title":"Dihydroergocryptine in the treatment of Parkinson's disease: a six months' double-blind clinical trial","volume":"14","author":"Martignoni","year":"1991","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1353-8020(00)00023-7","article-title":"Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicentre study","volume":"7","author":"Caraceni","year":"2001","journal-title":"Parkinsonism and Related Disorders"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1046\/j.1468-1331.1998.530255.x","article-title":"Does combined levodopa and bromocriptine therapy in Parkinson's disease prevent late motor complications?","volume":"5","author":"Alarcon","year":"1998","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00002826-199702000-00008","article-title":"Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage","volume":"20","author":"Gimenez-Roldan","year":"1997","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/jnnp.57.8.903","article-title":"The Sydney multicentre study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa","volume":"57","author":"Hely","year":"1994","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/jnnp.67.3.300","article-title":"The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years","volume":"67","author":"Hely","year":"1999","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1212\/WNL.57.9.1687","article-title":"Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial","volume":"57","author":"Lees","year":"2001","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.307.6902.469","article-title":"Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report","volume":"307","author":"Parkinson's Disease Research Group in the United Kingdom","year":"1993","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mds.20361","article-title":"Trial of Subtherapeutic Pergolide in de novo Parkinson's Disease","volume":"20","author":"Grosset","year":"2005","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.410380512","article-title":"The effect of deprenyl and levodopa on the progression of Parkinson's disease","volume":"38","author":"Olanow","year":"1995","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.1997.03550020057038","article-title":"Safety and efficacy of pramipexole in early Parkinson's disease: A randomised dose-ranging study","volume":"278","author":"Parkinson Study Group","year":"1997","journal-title":"The Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1212\/WNL.43.1_Part_1.21","article-title":"Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease","volume":"43","author":"Weiner","year":"1993","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00002826-199508000-00006","article-title":"Pramipexole in patients with early Parkinson's disease","volume":"18","author":"Hubble","year":"1995","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1212\/WNL.49.3.724","article-title":"Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group","volume":"49","author":"Shannon","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1212\/WNL.49.2.393","article-title":"Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group","volume":"49","author":"Adler","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0036|cit36","first-page":"S1-133 (P-TU-17","article-title":"Low incidence of dyskinesia in early Parkinson's disease treated with ropinirole","volume":"7","author":"Lucia","year":"2001","journal-title":"Parkinsonism and Related Disorders"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1600-0404.1978.tb02863.x","article-title":"Dopaminergic agonist Ro 8-4650 in Parkinson's disease. II. Patients not treated with dopa","volume":"58","author":"Presthus","year":"1978","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM198010303031804","article-title":"Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project","volume":"303","author":"Anonymous","year":"1980","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1056\/NEJM198911163212004","article-title":"Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group","volume":"321","author":"Anonymous","year":"1989","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1742-1241.2001.tb11025.x","article-title":"DICE 2: A further investigation of the effect of chance in life, death and subgroup analyses","volume":"55","author":"Clarke","year":"2001","journal-title":"International Journal of Clinical Practice"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006564.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/jnnp.72.suppl_1.i22","article-title":"Medical management of Parkinson's disease","volume":"72","author":"Clarke","year":"2002","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Systematic Reviews: Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0043|cit43","volume-title":"Treatment of Early Breast Cancer. Vol 1. Worldwide Evidence 1985-1990","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1990"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/096228029300200202","article-title":"The statistical basis of meta-analysis","volume":"2","author":"Fleiss","year":"1993","journal-title":"Statistical Methods in Medical Research"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/mds.10010","article-title":"Factors impacting on quality of life in Parkinson's disease: results from an international survey","volume":"17","author":"Global Parkinson's Disease Survey Steering Committee","year":"2002","journal-title":"Movement Disorders"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006564.pub2-BIB0046|cit46","first-page":"S89 (Abstract 3","article-title":"Drop-out bias undermines findings if improved functionality with cholinesterase inhibitors","volume":"23","author":"Hills","year":"2002","journal-title":"Neurobiology of Aging"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0140-6736(90)92095-Y","article-title":"Treatment adherence and risk of death after a myocardial infarction","volume":"336","author":"Horwitz","year":"1990","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0048|cit48","article-title":"The Parkinson's Disease Questionnaire. User manual for the PDQ-39, PDQ-8 and PDQ Summary Index","volume-title":"Health Services Research Unit","author":"Jenkinson","year":"1998"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0049|cit49","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1977.1","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples","volume":"35","author":"Peto","year":"1977","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","article-title":"Pramipexole vs. levodopa as initial treatment for Parkinson's disease: A randomized controlled trial","volume":"284","author":"Parkinson Study Group","year":"2000","journal-title":"The Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the Progress of Parkinson's Disease","volume":"351","author":"Parkinson Study Group","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0054|cit54","first-page":"1","article-title":"Parkinson's disease: clinical features","volume":"6","author":"Quinn","year":"1997","journal-title":"Baillieres Clinical Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006564.pub2-BIB0055|cit55","article-title":"Bromocriptine versus levodopa in early Parkinson's disease","author":"Ramaker","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006564.pub2-BIB0056|cit56","article-title":"Bromocriptine\/levodopa combined versus levodopa alone for early Parkinson's disease","author":"Ramaker","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(02)08520-3","article-title":"Treatment interventions for Parkinson's disease: an evidence based assessment","volume":"359","author":"Rascol","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/bmj.318.7179.311","article-title":"Science, medicine, and the future: Parkinson's disease","volume":"318","author":"Schapira","year":"1999","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006564.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1136\/bmj.324.7352.1508","article-title":"Evaluating drug treatments for Parkinson's disease: how good are the trials?","volume":"324","author":"Wheatley","year":"2002","journal-title":"BMJ"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006564.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T18:31:44Z","timestamp":1766687504000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006564.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Movement Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2008,4,23]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006564.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,23]]}}}